GlassScriptPhysician profile
Jane Jurma
NPI 1649777947
$921.13
in general payments reported to CMS, 2019-2025
25 companies · $49.47 in 2025
The $49.47 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.98 · 2022: $134 · 2023: $261 · 2024: $402 · 2025: $49.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $246.18 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $98.75 | 2021-2023 | Bexsero, Shingrix, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $57.34 | 2021-2024 | Trintellix |
| Exact Sciences Corporation | $48.46 | 2023-2024 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $42.94 | 2023-2024 | Jornay Pm |
| Corcept Therapeutics | $34.07 | 2024 | Korlym |
| Lundbeck LLC | $32.16 | 2022-2024 | Rexulti |
| Cranial Technologies, INC | $30.13 | 2024 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $29.90 | 2023-2024 | Flumist Quadrivalent |
| Axsome Therapeutics, INC. | $29.64 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $29.56 | 2024 | Rexulti |
| Pfizer INC. | $26.86 | 2024 | |
| Tempus Ai, INC | $26.68 | 2024 | |
| Sanofi-Aventis U.S. LLC | $26.25 | 2024 | |
| Collegium Pharmaceutical, INC. | $20.05 | 2025 | Jornay Pm |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $17.51 | 2023 | Venaseal |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.30 | 2024 | Caplyta |
| Abbvie INC. | $15.43 | 2021 | |
| Currax Pharmaceuticals LLC | $14.93 | 2023 | Contrave |
| Baxter Healthcare | $13.58 | 2022 | |
| Sanofi Pasteur INC. | $13.18 | 2022 | |
| Genzyme Corporation | $13.02 | 2023 | |
| Eisai INC. | $12.72 | 2021 | |
| Alk-Abello, INC | $12.70 | 2023 | Odactra, Ragwitek, Grastek |
| Acerus Pharmaceuticals Corporation | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Jurma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.